

## WEST Search History

DATE: Monday, February 11, 2002

Set Name Query  
side by side

Hit Count Set Name  
result set

*DB=USPT; PLUR=YES; OP=ADJ*

L9	L8 and vector	55	L9
L8	L7 and morphological	106	L8
L7	removable and marker	5122	L7
L6	L5 and (gvg or glucocorticoid)	19	L6
L5	L4 and marker	115	L5
L4	l2 and remov?	118	L4
L3	L2 and excis?	13	L3
L2	L1 and induc?	145	L2
L1	vector and recombinase and transcription factor	224	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal649axm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Sep 17 IMSworld Pharmaceutical Company Directory name change  
to PHARMASEARCH  
NEWS 3 Oct 09 Korean abstracts now included in Derwent World Patents  
Index  
NEWS 4 Oct 09 Number of Derwent World Patents Index updates increased  
NEWS 5 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File  
NEWS 6 Oct 22 Over 1 million reactions added to CASREACT  
NEWS 7 Oct 22 DGENE GETSIM has been improved  
NEWS 8 Oct 29 AAASD no longer available  
NEWS 9 Nov 19 New Search Capabilities USPATFULL and USPAT2  
NEWS 10 Nov 19 TOXCENTER(SM) - new toxicology file now available on STN  
NEWS 11 Nov 29 COPPERLIT now available on STN  
NEWS 12 Nov 29 DWPI revisions to NTIS and US Provisional Numbers  
NEWS 13 Nov 30 Files VETU and VETB to have open access  
NEWS 14 Dec 10 WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002  
NEWS 15 Dec 10 DGENE BLAST Homology Search  
NEWS 16 Dec 17 WELDASEARCH now available on STN  
NEWS 17 Dec 17 STANDARDS now available on STN  
NEWS 18 Dec 17 New fields for DPCI  
NEWS 19 Dec 19 CAS Roles modified  
NEWS 20 Dec 19 1907-1946 data and page images added to CA and Caplus  
NEWS 21 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web  
NEWS 22 Jan 25 Searching with the P indicator for Preparations  
NEWS 23 Jan 29 FSTA has been reloaded and moves to weekly updates  
NEWS 24 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update  
frequency  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:21:16 ON 11 FEB 2002

=> file agricola caplus biosis

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.15	0.15

FILE 'AGRICOLA' ENTERED AT 15:21:30 ON 11 FEB 2002

FILE 'CAPLUS' ENTERED AT 15:21:30 ON 11 FEB 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:21:30 ON 11 FEB 2002  
 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

=> s vector and recombinase  
 L1 507 VECTOR AND RECOMBINASE

=> s l1 and marker  
 L2 100 L1 AND MARKER

=> s l2 and (remov? or excis?)  
 L3 51 L2 AND (REMOV? OR EXCIS?)

=> dup rem l3  
 PROCESSING COMPLETED FOR L3  
 L4 38 DUP REM L3 (13 DUPLICATES REMOVED)

=> d 1-10 ti

L4 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Reporter gene-antibiotic resistance gene dual selection expression vectors  
 for easy screening of transformation

L4 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI **Vector** and method for targeted replacement and disruption of an  
 integrated DNA sequence

L4 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Inducible site-specific recombination for the activation and  
**removal** of transgenes in transgenic plants

L4 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Targeted **removal** of attP-flanked selectable **marker**  
 gene from a transgenic plant by inducing intrachromosomal homologous  
 recombination

L4 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Transgenic animals expressing modulating human Tau protein gene as models  
 for neurodegenerative disease such as Alzheimers

L4 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Mammalian retroviral vectors and their uses in study of gene expression

L4 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI A cloning system for the construction of vectors for mutation of  
 eukaryotic genes by homologous recombination

L4 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Improvement of the pBRINT-Ts plasmid family to obtain **marker**  
 -free chromosomal insertion of cloned DNA in E. coli

L4 ANSWER 9 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 TI Efficient elimination of selectable **marker** genes from the  
 plastid genome by the CRE-lox site-specific recombination system.

L4 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2002 ACS  
TI Mutant loxP vectors for selectable **marker** recycle and  
conditional knock-outs

=> d 3 so

L4 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2002 ACS  
SO PCT Int. Appl., 26 pp.  
CODEN: PIXXD2

=> d 3 pi

L4 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2002 ACS  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI WO 2001040492 A2 20010607 WO 2000-US42086 20001113  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

=> d 9 sop

'SOP' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid  
in at least one of the files. Refer to file specific help messages  
or the STNGUIDE file for information on formats available in  
individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):so

L4 ANSWER 9 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
SO Plant Journal, (July, 2001) Vol. 27, No. 2, pp. 171-178. print.  
ISSN: 0960-7412.

=> d 10 so

L4 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2002 ACS  
SO BMC Biotechnol. (2001), 1, No pp. given  
CODEN: BBMIE6; ISSN: 1472-6750  
URL: <http://www.biomedcentral.com/content/pdf/1472-6750-1-7.pdf>

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.83

16.98

FILE 'STNGUIDE' ENTERED AT 15:24:11 ON 11 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 8, 2002 (20020208/UP).

=> d 11-20 ti

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L4 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2002 ACS

TI Gene therapy of cancers using suicide genes preferentially deleted from non-cancerous cells

L4 ANSWER 12 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

TI Targeted integration of a GFP reporter into the SCA-1 locus results in high level expression in hematopoietic cells of transgenic mice.

L4 ANSWER 13 OF 38 AGRICOLA DUPLICATE 1

TI A transformation **vector** for the production of **marker** -free transgenic plants containing a single copy transgene at high frequency.

L4 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2

TI Intrachromosomal recombination between attP regions as a tool to **remove** selectable **marker** genes from tobacco transgenes

L4 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3

TI Exploring redundancy in the yeast genome: an improved strategy for use of the cre-loxP system

L4 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2002 ACS

TI Controlling gene expression in yeast by inducible site-specific recombination

L4 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4

TI Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains

L4 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2002 ACS

TI Recombinational cloning using nucleic acids having recombination sites

L4 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5

TI Chromosomal integration of heterologous DNA in Escherichia coli with precise **removal** of markers and replicons used during construction

L4 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 6

TI Genome engineering of Toxoplasma gondii using the site-specific **recombinase** Cre

=> d 11 so

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L4 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2002 ACS

SO Ger. Offen., 16 pp.  
CODEN: GWXXBX

=> d 11 pi

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L4 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2002 ACS

PATENT NO.            KIND    DATE                    APPLICATION NO.    DATE

```

-----
PI  DE 19834430      A1  20000203      DE 1998-19834430 19980730
    DE 19834430      C2  20000531
    WO 2000006758    A1  20000210      WO 1999-EP3607   19990525
        W: AU, CA, CN, JP, KR, RU, US
        RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
    AU 9943682      A1  20000221      AU 1999-43682    19990525
    AU 731510      B2  20010329
    EP 1019518      A1  20000719      EP 1999-926413   19990525
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI

```

=> d 13 so

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

```

L4  ANSWER 13 OF 38  AGRICOLA                      DUPLICATE 1
SO  The Plant journal : for cell and molecular biology, June 2000. Vol. 22,
    No. 5. p. 461-469
    Publisher: Oxford : Blackwell Sciences Ltd.
    ISSN: 0960-7412

```

=> d 16 so

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

```

L4  ANSWER 16 OF 38  CAPLUS  COPYRIGHT 2002 ACS
SO  Nucleic Acids Research (2000), 28(24), e108/1-e108/6
    CODEN: NARHAD; ISSN: 0305-1048

```

=> d 18 so

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

```

L4  ANSWER 18 OF 38  CAPLUS  COPYRIGHT 2002 ACS
SO  PCT Int. Appl., 186 pp.
    CODEN: PIXXD2

```

=> d 18 pi

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

```

L4  ANSWER 18 OF 38  CAPLUS  COPYRIGHT 2002 ACS
PATENT NO.      KIND  DATE      APPLICATION NO.  DATE
-----
PI  WO 9921977    A1    19990506      WO 1998-US22589 19981026
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
            KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
            MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
            TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 9911995      A1    19990517      AU 1999-11995    19981026

```

EP 1025217	A1	20000809	EP 1998-955110	19981026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
JP 2002500861	T2	20020115	JP 2000-518069	19981026
US 6277608	B1	20010821	US 1999-296280	19990422

=> d 18 ab

YOU HAVE REQUESTED DATA FROM FILE 'AGRICOLA, CAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L4 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2002 ACS

AB Recombinational cloning is provided by the use of nucleic acids, vectors and methods, in vitro and in vivo, for moving or exchanging segments of DNA mols. using engineered recombination sites and recombination proteins to provide chimeric DNA mols. that have the desired characteristic(s) and/or DNA segment(s). Reversible and/or repeatable cloning and subcloning reactions can be used to manipulate nucleic acids to form chimeric nucleic acids using recombination proteins and recombination sites. Recombinational cloning according to the present invention thus uses recombination proteins with recombinant nucleic acid mols. having at least one selected recombination site for moving or exchanging segments of nucleic acids mols., in vitro and in vivo. The methods of the invention provide a means in which nucleic acid mol. of interest may be moved or transferred into any no. of **vector** systems. Such transfer to various **vector** systems may be accomplished sep., sequentially, or in mass (e.g., into any no. of different vectors in one step). The improved specificity, speed and/or yields of the present invention facilitates DNA or RNA cloning, subcloning, regulation or exchange useful for any related purpose. Two different sets of plasmids were constructed to demonstrate the in vitro method. One set, for use with CRE **recombinase** only, contained loxP and loxP 511 sites. A second set, for use with Cre and integrase, contained loxP and att sites. The efficiency of prodn. of the desired daughter plasmid was about 60-fold higher using both enzymes than using Cre alone.

=> d 19 so y

L4 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5  
SO J. Bacteriol. (1999), 181(22), 7143-7148  
CODEN: JOBAAY; ISSN: 0021-9193

=> d 19 ab y

L4 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2002 ACS

DUPLICATE 5

AB A set of vectors which facilitates the sequential integration of new functions into the Escherichia coli chromosome by homologous recombination has been developed. These vectors are based on plasmids described by Posfai et al. (J. Bacteriol. 179:4426-4428, 1997) which contain conditional replicons (pSC101 or R6K), a choice of three selectable markers (ampicillin, chloramphenicol, or kanamycin), and a single FRT site. The modified vectors contain two FRT sites which bracket a modified multiple cloning region for DNA insertion. After integration, a helper plasmid expressing the flippase (FLP) **recombinase** allows precise in vivo **excision** of the replicon and the **marker** used for selection. Sites are also available for temporary insertion of addnl. functions which can be subsequently deleted with the replicon. Only the

DNA inserted into the multiple cloning sites (passenger genes and homologous fragment for targeting) and a single FRT site (68 bp) remain in the chromosome after **excision**. The utility of these vectors was demonstrated by integrating *Zymomonas mobilis* genes encoding the ethanol pathway behind the native chromosomal *adhE* gene in strains of *E. coli* K-12 and *E. coli* B. With these vectors, a single antibiotic selection system can be used repeatedly for the successive improvement of *E. coli* strains with precise deletion of extraneous genes used during construction.

=> d 21-30 ti y

- L4 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 7  
TI pBECKS2000: a novel plasmid series for the facile creation of complex binary vectors, which incorporates "clean-gene" facilities
- L4 ANSWER 22 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
TI Selectable **marker**-free transgenic plants without sexual crossing: Transient expression of *cre* **recombinase** and use of a conditional lethal dominant gene.
- L4 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2002 ACS  
TI Retrovirus-based expression vectors for use in the study of gene expression in mammalian cells
- L4 ANSWER 24 OF 38 CAPLUS COPYRIGHT 2002 ACS  
TI Preparation of adeno-associated virus-derived **vector** for introducing genes into animal cells using *cre/loxP* mechanism and its use in gene therapy
- L4 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2002 ACS  
TI Conditional immortalization method for human tumor cells in producing a vaccine
- L4 ANSWER 26 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
TI Retargeting of retroviral integration sites for the predictable expression of transgenes and the analysis of *cis*-acting sequences.
- L4 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2002 ACS  
TI Inducible expression based on regulated recombination: a single **vector** strategy for stable expression in cultured cells
- L4 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 8  
TI Dissecting the role of N-myc in development using a single targeting **vector** to generate a series of alleles
- L4 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2002 ACS  
TI Regulated **excision** of a target gene from the transformation **vector** in the recipient cell using a site-specific **recombinase**
- L4 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 9  
TI *Cre/loxP*-mediated **excision** of a neomycin resistance expression unit from an integrated retroviral **vector** increases long terminal repeat-driven transcription in human hematopoietic cells

=> d 22 aB Y

- L4 ANSWER 22 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.



AB Transgenic tobacco plants were produced that contained single-copy pART54 T-DNA, with a 35S-uidA gene linked to loxP-flanked kanamycin resistance (nptII) and cytosine deaminase (codA) genes. Retransformation of these plants with pCre1 (containing 35S transcribed cre **recombinase** and hygromycin (hpt) resistance genes) resulted in **excision** of the loxP-flanked genes from the genome. Phenotypes of progeny from selfed-retransformed plants confirmed nptII and codA **excision** and integration of the cre-linked hpt gene. To avoid integration of the hpt gene, and thereby generate plants totally free of **marker** genes, we attempted to transiently express the cre **recombinase**. Agrobacterium tumefaciens (pCre1) was cocultivated with leaf discs of two pART54-transformed lines and shoots were regenerated in the absence of hygromycin selection. Nineteen of 773 (0.25%) shoots showed tolerance to 5-fluorocytosine (5-fc) which is converted to the toxic 5-fluorouracil by cytosine deaminase. 5-fc tolerance in six shoots was found to be due to **excision** of the loxP-flanked region of the pART54 T-DNA. In four of these shoots **excision** could be attributed to cre expression from integrated pCre1 T-DNA, whereas in two shoots **excision** appeared to be a consequence of transient cre expression from pCre1 T-DNA molecules which had been transferred to the plant cells but not integrated into the genome. The absence of selectable **marker** genes was confirmed by the phenotype of the T1 progeny. Therefore, through transient cre expression, **marker**-free transgenic plants were produced without sexual crossing. This approach could be applicable to the elimination of **marker** genes from transgenic crops which must be vegetatively propagated to maintain their elite genotype.

=> d 27 ab y

L4 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2002 ACS

AB When fused to the ligand binding domain (LBD) of steroid hormone nuclear receptors, site-specific recombinases (SSRs) acquire a ligand-dependent activity. Here, the authors describe the use of SSR-LBD fusion proteins in an inducible expression system, introduced into cells in a single step. A single transgene contains a constitutively active, bi-directional enhancer/promoter, which directs expression, on one side, of an SSR-LBD fusion protein gene and, on the other, a selectable **marker** /inducible gene cassette. The selectable **marker**, the puromycin acetyltransferase (pac) gene, is used for stable genomic integration of the transgene and is flanked by recombination target sites. The inducible gene is not expressed because the pac gene lies between it and the promoter. Activation of the SSR-LBD by a ligand induces recombination and the pac gene is **excised**. The inducible gene is thus positioned next to the promoter and so is expressed. This describes a ligand-inducible expression strategy that relies on regulated recombination rather than regulated transcription. By inducible expression of diphtheria toxin, evidence that this system permits inducible expression of very toxic proteins is presented. The combination of the complete regulatory circuit and inducible gene in one transgene relates expression of the selectable **marker** gene to expression from the bi-directional enhancer/promoter. The authors exploit this relationship to show that graded increases in selection pressure can be used to select for clones with different induction properties.

=> d 29 ab y

L4 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2002 ACS

AB A method of site-specific **excision** of a target gene from a

transformation **vector** using a site-specific **recombinase** is described. This allows the transformation of the target organism with the **removal** of a selectable **marker** carried by the **vector**. **Excision** can be regulated or constitutive depending upon the promoter regulating the **recombinase** gene. As a result the same selectable **marker** can be used in a no. of sequential transformations. The method can be generally used to regulate transgene expression in genetically-manipulated organisms, for example to promote differentiation, de-differentiation, or any unidirectional developmental shift of a target cell which requires the time-specific expression of a particular gene. The method is particularly suited to the promotion of specific organogeneses in plants using organogenesis-promoting transgenes, wherein the organs which subsequently develop in said plants are genetically transformed with a desired gene but lack organogenesis-promoting transgenes. The use flp/frt and cre/loxP recombination systems in tobacco (*Nicotiana plumbaginifolia*) is demonstrated.

=> d 29 so y

L4 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 SO PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2

=> d 29 pi y

L4	ANSWER 29 OF 38 CAPLUS COPYRIGHT 2002 ACS				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 9737012	A1	19971009	WO 1997-AU197	19970327
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250111	AA	19971009	CA 1997-2250111	19970327
	AU 9721437	A1	19971022	AU 1997-21437	19970327
	AU 717267	B2	20000323		
	EP 922097	A1	19990616	EP 1997-913984	19970327
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 2000507446	T2	20000620	JP 1997-534743	19970327

=> d 31-38 ti y

L4 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Transient expression of SV 40 large T antigen by Cre/LoxP-mediated site-specific deletion in primary human tumor cells

L4 ANSWER 32 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 10  
 TI Positive selection of FLP-mediated unequal sister chromatid exchange products in mammalian cells

L4 ANSWER 33 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 11  
 TI **Excision** of an integrated provirus by the action of FLP  
**recombinase**

L4 ANSWER 34 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 12  
 TI Self-deleting retrovirus vectors for gene therapy

L4 ANSWER 35 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI **Excision** of specific DNA-sequences from integrated retroviral  
 vectors via site-specific recombination

L4 ANSWER 36 OF 38 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 TI **Excision** of specific DNA-sequences from integrated retroviral  
 vectors via site-specific recombination.

L4 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI Recycling selectable markers in yeast

L4 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 TI A series of yeast/*Escherichia coli* .lambda. expression vectors designed  
 for directional cloning of cDNAs and cre/lox-mediated plasmid  
**excision**

=> d 37 ab y

L4 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 AB A series of **excisable marker** cassettes has been  
 constructed to facilitate recycling of selectable markers in yeast. These  
 cassettes exploit the use of the Cre DNA **recombinase** to  
 precisely **excise** the **marker** gene when desired. They  
 are esp. useful for making gene disruptions and then **removing**  
 the **marker** gene to allow subsequent genetic manipulations with  
 that same **marker**. Also described are a no. of cre expression  
 vectors that allow galactose-induced expression of the **recombinase**  
 in yeast. The procedure is simple and allows rapid processing of large  
 nos. of transformants.

=> d 37 pi y

L4 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2002 ACS

=> d 37 so y

L4 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2002 ACS  
 SO BioTechniques (1994), 16(6), 1086-8  
 CODEN: BTNQDO; ISSN: 0736-6205

=> s transcription factor and recombinase and vector  
     0 TRANSCRIPTION  
     6 FACTOR  
     0 TRANSCRIPTION FACTOR  
       (TRANSCRIPTION(W) FACTOR)  
     0 RECOMBINASE  
     0 VECTOR

L5 0 TRANSCRIPTION FACTOR AND RECOMBINASE AND VECTOR

=> s transcription factor and recombina

0 TRANSCRIPTION

6 FACTOR

0 TRANSCRIPTION FACTOR

(TRANSCRIPTION(W) FACTOR)

0 RECOMBINASE

L6 0 TRANSCRIPTION FACTOR AND RECOMBINASE

=> file agricola caplus biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.00

69.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.10

FILE 'AGRICOLA' ENTERED AT 15:39:08 ON 11 FEB 2002

FILE 'CAPLUS' ENTERED AT 15:39:08 ON 11 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:39:08 ON 11 FEB 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s transcription factor and recombina

L7 4 TRANSCRIPTION FACTOR AND RECOMBINASE AND VECTOR

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 4 DUP REM L7 (0 DUPLICATES REMOVED)

=> d 1-4 ti

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

TI Inducible site-specific recombination for the activation and removal of transgenes in transgenic plants

L8 ANSWER 2 OF 4 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

TI Apoptosis induced by p75 vs NGF withdrawal: Differential mechanisms revealed by c-jun deletion.

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

TI Gene therapy of cancers using suicide genes preferentially deleted from non-cancerous cells

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

TI Eukaryote persistent gene expression or gene regulation using vectors comprising origin of replication, gene of interest, and gene for site-specific **recombinase** or other replication protein

=> d so

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

S0 PCT Int. Appl., 26 pp.

CODEN: PIXXD2

=> d pi

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040492	A2	20010607	WO 2000-US42086	20001113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

=> d 4 so

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS  
 SO PCT Int. Appl., 120 pp.  
 CODEN: PIXXD2

=> d 4 piu  
 'PIU' IS NOT A VALID FORMAT  
 In a multifile environment, a format can only be used if it is valid  
 in at least one of the files. Refer to file specific help messages  
 or the STNGUIDE file for information on formats available in  
 individual files.  
 REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):pi

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709439	A1	19970313	WO 1996-US14123	19960827
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA US 5801030 A 19980901 US 1995-522684 19950901 AU 9669122 A1 19970327 AU 1996-69122 19960827 AU 717597 B2 20000330 EP 850312 A1 19980701 EP 1996-929879 19960827 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE CN 1200149 A 19981125 CN 1996-197732 19960827 JP 2001507203 T2 20010605 JP 1997-511335 19960827 US 6063627 A 20000516 US 1998-30563 19980225 NO 9800838 A 19980421 NO 1998-838 19980227				

=> d 4 ab

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS  
 AB The present invention provides methods for site-specific recombination in  
 a cell, as well as vectors which can be employed in such methods. The  
 methods and vectors of the present invention can be used to obtain  
 persistent gene expression in a cell and to modulate gene expression. One  
 preferred method according to the invention comprises contacting a cell  
 with a **vector** comprising an origin of replication functional in  
 mammalian cells located between first and second recombining sites located  
 in parallel. Another preferred method comprises, in part, contacting a

cell with a **vector** comprising first and second recombining sites in antiparallel orientations such that the **vector** is internalized by the cell. In both methods, the cell is further provided with a site-specific **recombinase** that effects recombination between the first and second recombining sites of the **vector**.

=> s transcription factor and recombinase

L9 74 TRANSCRIPTION FACTOR AND RECOMBINASE

=> l9 and (excis? or remov?)

L9 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l9 and (excis? or remov?)

L10 11 L9 AND (EXCIS? OR REMOV?)

=> dup rem l10

PROCESSING COMPLETED FOR L10

L11 9 DUP REM L10 (2 DUPLICATES REMOVED)

=> d 1-9 ti

L11 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Inducible site-specific recombination for the activation and **removal** of transgenes in transgenic plants

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS

DUPLICATE 1

TI Conditional deletion of the bcl-x gene from mouse mammary epithelium results in accelerated apoptosis during involution but does not compromise cell function during lactation

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Gene therapy of cancers using suicide genes preferentially deleted from non-cancerous cells

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Isolation of target nucleic acid molecules using hairpin-type nucleic acid probes

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Glucocorticoid receptor with modified ligand specificity, fusion proteins containing the ligand binding domain thereof, and their use in controlling gene expression in recombinant cells and transgenic animals

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Reporter gene systems for assaying the effectiveness of a transcription regulating factor and their uses

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Measuring the activity of transcription regulatory factors with reporter genes and regulatory cascades

L11 ANSWER 8 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

TI Expression of the Drosophila gooseberry locus defines a subset of neuroblast lineages in the central nervous system.

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS

DUPLICATE 2

TI The Bacillus subtilis gene for the developmental **transcription factor** .sigma.K is generated by **excision** of a dispensable DNA element containing a sporulation **recombinase** gene

=> d 5 so

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS  
SO PCT Int. Appl., 99 pp.  
CODEN: PIXXD2

=> d 5 pi

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731108	A1	19970828	WO 1997-FR315	19970220
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2745008	A1	19970822	FR 1996-2060	19960220
CA 2247517	AA	19970828	CA 1997-2247517	19970220
AU 9720989	A1	19970910	AU 1997-20989	19970220
AU 707684	B2	19990715		
EP 896620	A1	19990217	EP 1997-906232	19970220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000505298	T2	20000509	JP 1997-529854	19970220

=> d 5 ab

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

AB A DNA fragment coding for a modified nuclear glucocorticoid receptor, particularly one mutated in the region coding for the ligand binding domain, so that receptor activity is more strongly inducible by a synthetic glucocorticoid ligand than by a natural glucocorticoid ligand, is disclosed. A fusion protein between the modified ligand-binding domain of the glucocorticoid receptor and a DNA-binding domain may be used to control gene expression in recombinant cells or in transgenic animals. A recombination system inducible in mammals by means of a fusion protein produced between a **recombinase** and the binding domain of the ligand derived from the modified glucocorticoid receptor of which the activity is more strongly inducible by synthetic glucocorticoids than by natural glucocorticoids, is also disclosed. The human glucocorticoid receptor contg. threonine at position 747 instead of isoleucine displays normal transactivating activity with dexamethasone, but not with natural ligands aldosterone and corticosterone. COS-7 cells contg. a reporter gene controlled by a GRE were exposed to dexamethasone or corticosterone. Reporter gene expression was only obsd. with the synthetic glucocorticoid. Control of genetic recombination (i.e., **excision** of loxP-flanked gene insert) in cells or transgenic mice by modified glucocorticoid receptor ligand binding domain fused to Cre **recombinase** was also demonstrated.

=> d 6 ab

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

AB A method of detg. the activity of a regulatory factor that uses a set of reporter genes under control of different arrays of regulatory elements is described. The method uses two regulatory factors in a cascade in which an active first factor affects either the activity of the second regulatory factor, or the expression of the gene encoding it. It is the second factor that regulates expression of the reporter gene. Following addn. of an inhibitor, the activation of the reporter system is detected by the interaction between the first and second regulatory factors. The

method can be used to identify factors that can inhibit the action of oncogene products that are transcription factors. The development of *Saccharomyces cerevisiae*-based test systems is described. The use of such a system to screen a pool of .apprx.105 peptides for inhibitors of the **transcription factor** CTF-7 is demonstrated.

=> d 7 ab

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS

AB A method for measuring the activity of a **transcription factor** that uses a regulatory cascade with factor of interest as the first component of the cascade is described. The factor is used to regulate expression of a gene that is used to control expression of a reporter gene. The use of the cascade allows the measurement of transcription activating and inhibiting activities and of multi-component factors. The assay is adaptable to screening large nos. of compds. affecting transcription for use in the therapeutic regulation of gene expression, e.g. inhibition of oncogene function. The second regulatory protein may be a fusion protein of two factors intended to give maximal reporting of the activity of the first **transcription factor**.a. Models for testing a no. of regulatory interactions are presented. *Saccharomyces cerevisiae* is the preferred host, allowing for large scale screening of compds. Model systems showing tetracycline regulation of expression through the tetR repressor and for screening of peptide inhibitors of CTF-7 function are demonstrated.

=> s (gvg or glucocorticoid) and recombinase

L12 16 (GVG OR GLUCOCORTICOID) AND RECOMBINASE

=> dup rem l12

PROCESSING COMPLETED FOR L12

L13 12 DUP REM L12 (4 DUPLICATES REMOVED)

=> s l13 and transcription factor

L14 3 L13 AND TRANSCRIPTION FACTOR

=> del l14 y

=> d 1-12 ti

L13 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS

TI Mutation of the cre gene to remove cryptic splice sites to improve the expression and inducibility of the gene in eukaryotic hosts

L13 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

TI Inducible site-specific recombination for the activation and removal of transgenes in transgenic plants

L13 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS

TI Methods of genetic manipulations of living systems using fusion of recombinases and regulatory ligand binding domain

L13 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS

TI Non-human mammal with tissue-specific modified **glucocorticoid** receptor and its use in development of disease treatments

L13 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS

TI Expression of the 11.beta.-hydroxysteroid dehydrogenase 2 gene in the mouse

L13 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS

TI Expression of cre **recombinase** as a reporter of signal



transduction in mammalian cells

L13 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
TI A chimeric Cre **recombinase** inducible by synthetic, but not by natural ligands of the **glucocorticoid** receptor

L13 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3  
TI Genetic recombination as a reporter for screening steroid receptor agonists and antagonists

L13 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS  
TI **Glucocorticoid** receptor with modified ligand specificity, fusion proteins containing the ligand binding domain thereof, and their use in controlling gene expression in recombinant cells and transgenic animals

L13 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4  
TI SNF2.beta.-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells

L13 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS  
TI Steroid receptor knockouts

L13 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
TI Ligand-regulated site-specific recombination.

=> d 2 ab

L13 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS  
AB Disclosed is an inducible promoter system in conjunction with a site-specific recombination system which allows (i) specific activation of transgenes at specific times or (ii) excision and removal of transgenes (e.g., antibiotic resistance markers) from transgenic plants. These "suicide" gene cassettes, including the recombination system itself, can be evicted from the plant genome once their function has been exerted. The system is based on the ability to temporally and spatially induce the expression of CRE **recombinase** which then binds to directly repeated lox sites flanking the transgene in question leading to the precise excision of the gene cassette. Also disclosed is a method to activate an inverted, and therefore silent, transgene by placing two lox sites in opposite orientations flanking the transgene. This results in inversion of the intervening DNA fragment in the presence of CRE **recombinase**. This activation can be timed by placing the CRE **recombinase** under the control of an inducible promoter. In order to test this system a construct was designed that allows in planta monitoring of precise excision events using the firefly luciferase (LUC) reporter gene as a marker for recombination.

=> d 2 so

L13 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS  
SO PCT Int. Appl., 26 pp.  
CODEN: PIXXD2

=> d 2 pi

L13 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040492	A2	20010607	WO 2000-US42086	20001113

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

=> d 7 so

L13 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
 SO Nucleic Acids Res. (1998), 26(17), 4086-4090  
 CODEN: NARHAD; ISSN: 0305-1048

=> d 7 ab

L13 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
 AB The authors have developed a new ligand-dependent chimeric  
**recombinase** (Cre-GRdex) by fusing the site-specific Cre  
**recombinase** to the ligand binding domain (LBD) of a mutant human  
**glucocorticoid** receptor (GRdex). The synthetic  
**glucocorticoid** receptor (GR) ligands dexamethasone, triamcinolone  
 acetonide and RU38486 efficiently induce **recombinase** activity in  
 F9 murine embryonal carcinoma cells expressing constitutively Cre-GRdex.  
 In contrast, no **recombinase** activity was detected in the absence  
 of ligand or in the presence of the natural GR ligands corticosterone,  
 cortisol or aldosterone. Moreover, physiol. concns. of these natural GR  
 ligands do not affect Cre-GRdex **recombinase** activity induced by  
 dexamethasone. Thus, as previously shown using Cre-estrogen receptor (ER)  
 fusion proteins, Cre-GRdex might be useful for achieving loxP  
 site-directed mutagenesis in cultured cells and spatio-temporally  
 controlled somatic cell mutagenesis in transgenic mice.

=> d 12 ab

L13 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AB Site-specific recombination offers a potential way to alter a living  
 genome by design in a precise and stable manner. This potential requires  
 strategies which can be used to regulate the recombination event. We  
 describe a strategy to regulate FLP **recombinase** activity which  
 relies on expressing FLP as a fusion protein with steroid hormone receptor  
 ligand binding domains (LBDs). In the absence of a ligand cognate to the  
 LBD, the **recombinase** activity of the fusion protein is extremely  
 low. Upon ligand administration, **recombinase** activity is rapidly  
 induced. These results outline the basis for inducible expression or  
 disruption strategies based on inducible recombination. Additionally, we  
 have exploited the conditional nature of FLP-LBD fusion proteins to direct  
 integration of a plasmid into a specific genomic site at frequencies  
 approaching the frequency of random integration.

=> s ((moller s?) or (moller, s?))/au  
 L14 453 ((MOLLER S?) OR (MOLLER, S?))/AU

=> s l14 and recombinase  
 L15 4 L14 AND RECOMBINASE

=> dup rem l15  
 PROCESSING COMPLETED FOR L15  
 L16 2 DUP REM L15 (2 DUPLICATES REMOVED)

=> d 1-2 ti

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

TI Inducible site-specific recombination for the activation and removal of  
transgenes in transgenic plants

L16 ANSWER 2 OF 2 AGRICOLA

DUPLICATE 1

TI Chemical-regulated, site-specific DNA excision in transgenic plants.

=> d 2 so

L16 ANSWER 2 OF 2 AGRICOLA

DUPLICATE 1

SO Nature biotechnology, Feb 2001. Vol. 19, No. 2. p. 157-161

Publisher: New York, NY : Nature America, Inc.

CODEN: NABIF9; ISSN: 1087-0156

[Help](#)
[Logout](#)
[Interrupt](#)
[Main Menu](#)
[Search Form](#)
[Posting Counts](#)
[Show S Numbers](#)
[Edit S Numbers](#)
[Preferences](#)

## Search Results -

Terms	Documents
chemical inducible and (gvg or glucocorticoid)	1

Database: 
 US Patents Full-Text Database  
 US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

[Refine Search:](#)
chemical inducible and (gvg or glucocorticoid)
[Clear](#)

## Search History

Today's Date: 6/1/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	chemical inducible and (gvg or glucocorticoid)	1	<a href="#">L8</a>
USPT	l6 and gvg inducible	0	<a href="#">L7</a>
USPT	l4 and chemical	450	<a href="#">L6</a>
USPT	l4 and recombinase	29	<a href="#">L5</a>
USPT	l3 and induc?	484	<a href="#">L4</a>
USPT	(gvg or glucocor\$) and plant	962	<a href="#">L3</a>
USPT	(gvg or glucocor?) and plant	5	<a href="#">L2</a>
USPT	(( (( (vector and recombinase and transcription factor ) and (remov? or excis?) ) ) and plant ) and induc? )	42	<a href="#">L1</a>

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
l6 and induc?	42

Database: 
 US Patents Full-Text Database  
 US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

[Refine Search:](#)[Clear](#)**Search History****Today's Date: 5/28/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	l6 and induc?	42	<u>L7</u>
USPT	l1 and plant	50	<u>L6</u>
USPT	l4 and marker and excis?	15	<u>L5</u>
USPT	recombinase and transcription factor	160	<u>L4</u>
USPT	(excis? adj5 marker) and recombinase	1	<u>L3</u>
USPT	excis? adj5 marker gene	1	<u>L2</u>
USPT	((vector and recombinase and transcription factor) and (remov? or excis?))	125	<u>L1</u>